Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2014-01-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2014.873790PMID 24354659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases

  2013cited by this paper
• Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders

  2013cited by this paper
• Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy

  2013cited by this paper
• Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

  2013cited by this paper
• A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

  2013cited by this paper
• The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

  2012cited by this paper
• Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia

  2012cited by this paper
• Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.

  2012cited by this paper
• Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

  2012cited by this paper
• Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia

  2012cited by this paper
• Retracted: Effect of blonanserin on cognitive function in antipsychotic‐naïve first‐episode schizophrenia

  2012cited by this paper
• Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder

  2012cited by this paper
• Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia

  2012cited by this paper
• Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112

  2012cited by this paper
• The Physiology, Signaling, and Pharmacology of Dopamine Receptors

  2011cited by this paper
• Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine

  2011cited by this paper
• A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

  2011cited by this paper
• The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia

  2011cited by this paper
• THE SOCIOLOGICAL PERSPECTIVE

  2011cited by this paper
• Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial

  2010cited by this paper
• Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.

  2010cited by this paper
• Title: Does the difference between physically active and couch potato lie in the dopamine system?

  2010cited by this paper
• Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.

  2010cited by this paper
• Progress in Defining Optimal Treatment Outcome in Schizophrenia

  2010cited by this paper
• Blonanserin

  2010cited by this paper
• Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.

  2010cited by this paper
• Effect of bromocriptine on antipsychotic drug‐induced hyperprolactinemia: Eight‐week randomized, single‐blind, placebo‐controlled, multicenter study

  2010cited by this paper
• Mental Health Care in the Aftermath of Deinstitutionalization: A Retrospective and Prospective View

  2010cited by this paper
• L-Dopa Medication in Parkinson's Disease Restores Activity in the Motor Cortico-Striatal Loop but Does Not Modify the Cognitive Network

  2009cited by this paper
• Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

  2009cited by this paper
• The American Psychiatric Publishing Textbook of Psychopharmacology

  2009cited by this paper
• Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.

  2009cited by this paper
• The dopamine hypothesis of schizophrenia: version III--the final common pathway.

  2009cited by this paper
• Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

  2009cited by this paper
• The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.

  2009cited by this paper
• Schizophrenia

  2009cited by this paper
• EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

  2009cited by this paper
• The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia

  2009cited by this paper
• Akt/GSK3 signaling in the action of psychotropic drugs.

  2009cited by this paper
• Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

  2008cited by this paper
• The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.

  2007cited by this paper
• The debate over dopamine’s role in reward: the case for incentive salience

  2007cited by this paper
• Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits

  2007cited by this paper
• Neurobiology of dopamine in schizophrenia.

  2007cited by this paper
• The history of clozapine and its emergence in the US market

  2007cited by this paper
• Once and future signaling

  2007cited by this paper
• Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac?

  2007cited by this paper
• Functions of mesolimbic dopamine: changing concepts and shifting paradigms

  2007cited by this paper
• Effects of Methylphenidate on Cognitive Function and Gait in Patients With Parkinson's Disease: A Pilot Study

  2006cited by this paper
• Current treatment issues in female hyperprolactinaemia.

  2006cited by this paper
• Brain dopamine d1 receptors in twins discordant for schizophrenia.

  2006cited by this paper
• The neurobiology of cognition in schizophrenia.

  2006cited by this paper
• The neurobiology of cognition in schizophrenia.

  2006cited by this paper
• Antischizophrenic Drugs : Chronic Treatment Elevates Dopamine Receptor Binding in Brain

  2006cited by this paper
• The mesolimbic dopamine reward circuit in depression.

  2006cited by this paper
• History of the discovery and clinical introduction of chlorpromazine.

  2005cited by this paper
• 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms

  2005cited by this paper
• Dopamine, learning and motivation

  2004cited by this paper
• Dopamine Receptor Signaling

  2004cited by this paper
• Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging.

  2004cited by this paper
• Neurotransmitters, Receptors, Signal Transduction, and Second Messengers in Psychiatric Disorders.

  2004cited by this paper
• A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications

  2004cited by this paper
• Do we still believe in the dopamine hypothesis? New data bring new evidence.

  2004cited by this paper
• Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.

  2004cited by this paper
• Event-related FMRI study of context processing in dorsolateral prefrontal cortex of patients with schizophrenia.

  2003cited by this paper
• Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down.

  2003cited by this paper
• Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia.

  2003cited by this paper
• Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia.

  2003cited by this paper
• RGS Proteins: G Protein-Coupled Receptors Meet Their Match

  2003cited by this paper
• Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients

  2003cited by this paper
• Recent evidence for dopamine abnormalities in schizophrenia

  2002cited by this paper
• Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study.

  2002cited by this paper
• Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia

  2002cited by this paper
• Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

  2002cited by this paper
• Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors.

  2002cited by this paper
• The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals.

  2002cited by this paper
• Dopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings

  2001cited by this paper
• Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

  2001influential reference
• [Selective attention deficit in schizophrenia].

  2001cited by this paper
• An event-related functional magnetic resonance imaging study of an auditory oddball task in schizophrenia.

  2001cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Cognition in schizophrenia

  2001cited by this paper
• Steady-state visually evoked potential topography during the continuous performance task in normal controls and schizophrenia.

  2000cited by this paper
• Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

  2000cited by this paper
• Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.

  1999cited by this paper
• PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756

  1999cited by this paper
• Attenuated frontal activation in schizophrenia may be task dependent.

  1999cited by this paper
• New insights into dopaminergic receptor function using antisense and genetically altered animals.

  1999cited by this paper
• Physiological characteristics of capacity constraints in working memory as revealed by functional MRI.

  1999cited by this paper
• Increased dopamine transmission in schizophrenia: relationship to illness phases.

  1999cited by this paper
• Lifetime regulation of G protein-effector complex: emerging importance of RGS proteins.

  1998cited by this paper
• Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

  1998cited by this paper
• Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study

  1998cited by this paper
• The D2 receptor: love it and leave it

  1998cited by this paper
• Dopamine D2 densities and the schizophrenic brain.

  1998cited by this paper
• Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

  1998cited by this paper
• Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil.

  1998cited by this paper
• Dopamine receptors: from structure to function.

  1998cited by this paper
• Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients.

  1998cited by this paper
• Decreased frontal activation of schizophrenics during stimulation with the continuous performance test—A functional magnetic resonance imaging study

  1998cited by this paper

• Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials

  2025cites this paper
• Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis

  2022cites this paper
• Geriatric Pharmacology

  2020cites this paper
• DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis

  2020cites this paper
• Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing

  2018cites this paper
• Investigational dopamine antagonists for the treatment of schizophrenia

  2017cites this paper
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cites this paper
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cites this paper